FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

Cell Reports

Volumn 3, Issue 6, 2013, Pages 1766-1776

  Mead, AdamJ ^a   Kharazi, Shabnam ^b   Atkinson, Deborah ^a   Macaulay, Iain ^a   Pecquet, Christian ^c,d   Loughran, Stephen ^a   Lutteropp, Michael ^a   Woll, Petter ^a   Chowdhury, Onima ^a   Luc, Sidinh ^a   Buza Vidas, Natalija ^a   Ferry, Helen ^a   Clark, Sally Ann ^a   Goardon, Nicolas ^a   Vyas, Paresh ^a   Constantinescu, StefanN ^c,d   Sitnicka, Ewa ^b   Nerlov, Claus ^a,e   Jacobsen, StenEirikW ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL TRANSFORMATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOPOIESIS; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICROARRAY ANALYSIS; MULTIPOTENT STEM CELLS; MYELOID CELLS; SIGNAL TRANSDUCTION;

EID: 84879797933     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.04.031     Document Type: Article

References (33)

1. Adolfsson J., Månsson R., Buza-Vidas N., Hultquist A., Liuba K., Jensen C.T., Bryder D., Yang L., Borge O.J., Thoren L.A., et al. Identificationof Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005, 121:295-306.
2. Chu S.H., Heiser D., Li L., Kaplan I., Collector M., Huso D., Sharkis S.J., Civin C., Small D. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell 2012, 11:346-358.
3. Croce C.M. Oncogenes and cancer. N.Engl. J. Med. 2008, 358:502-511.
4. DeKoter R.P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000, 288:1439-1441.
5. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
6. Enver T., Jacobsen S.E. Developmental biology: Instructions writ in blood. Nature 2009, 461:183-184.
7. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., Linch D.C. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784. Medical Research Council Adult Leukaemia Working Party.
8. Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., Woll P., Mead A., Alford K.A., Rout R., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
9. Grossmann V., Kern W., Harbich S., Alpermann T., Jeromin S., Schnittger S., Haferlach C., Haferlach T., Kohlmann A. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica 2011, 96:1874-1877.
10. Growney J.D., Shigematsu H., Li Z., Lee B.H., Adelsperger J., Rowan R., Curley D.P., Kutok J.L., Akashi K., Williams I.R., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005, 106:494-504.
11. Hegde S., Ni S., He S., Yoon D., Feng G.S., Watowich S.S., Paulson R.F., Hankey P.A. Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene 2009, 28:3349-3359.
12. Jacob B., Osato M., Yamashita N., Wang C.Q., Taniuchi I., Littman D.R., Asou N., Ito Y. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood 2010, 115:1610-1620.
13. Jan M., Snyder T.M., Corces-Zimmerman M.R., Vyas P., Weissman I.L., Quake S.R., Majeti R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 2012, 4. 149ra118.
14. Kharazi S., Mead A.J., Mansour A., Hultquist A., Böiers C., Luc S., Buza-Vidas N., Ma Z., Ferry H., Atkinson D., et al. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood 2011, 118:3613-3621.
15. Kiel M.J., Yilmaz O.H., Iwashita T., Yilmaz O.H., Terhorst C., Morrison S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005, 121:1109-1121.
16. Kundu M., Compton S., Garrett-Beal L., Stacy T., Starost M.F., Eckhaus M., Speck N.A., Liu P.P. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma. Blood 2005, 106:3621-3624.
17. Lee B.H., Tothova Z., Levine R.L., Anderson K., Buza-Vidas N., Cullen D.E., McDowell E.P., Adelsperger J., Fröhling S., Huntly B.J., et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007, 12:367-380.
18. Leow S., Kham S.K., Ariffin H., Quah T.C., Yeoh A.E. FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia-a study of 531 Southeast Asian children by the Ma-Spore study group. Hematol. Oncol. 2011, 29:211-219.
19. Levis M., Murphy K.M., Pham R., Kim K.T., Stine A., Li L., McNiece I., Smith B.D., Small D. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005, 106:673-680.
20. Li L., Piloto O., Nguyen H.B., Greenberg K., Takamiya K., Racke F., Huso D., Small D. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood 2008, 111:3849-3858.
21. Luc S., Luis T.C., Boukarabila H., Macaulay I.C., Buza-Vidas N., Bouriez-Jones T., Lutteropp M., Woll P.S., Loughran S.J., Mead A.J., et al. The earliest thymic Tcell progenitors sustain B cell and myeloid lineage potential. Nat. Immunol. 2012, 13:412-419.
22. Månsson R., Hultquist A., Luc S., Yang L., Anderson K., Kharazi S., Al-Hashmi S., Liuba K., Thorén L., Adolfsson J., et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 2007, 26:407-419.
23. Pecquet C., Staerk J., Chaligné R., Goss V., Lee K.A., Zhang X., Rush J., Van Hees J., Poirel H.A., Scheiff J.M., et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010, 115:1037-1048.
24. Putz G., Rosner A., Nuesslein I., Schmitz N., Buchholz F. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 2006, 25:929-939.
25. Rieger M.A., Hoppe P.S., Smejkal B.M., Eitelhuber A.C., Schroeder T. Hematopoietic cytokines can instruct lineage choice. Science 2009, 325:217-218.
26. Rumfelt L.L., Zhou Y., Rowley B.M., Shinton S.A., Hardy R.R. Lineage specification and plasticity in CD19- early B cell precursors. J.Exp. Med. 2006, 203:675-687.
27. Schmidt-Arras D., Böhmer S.A., Koch S., Müller J.P., Blei L., Cornils H., Bauer R., Korasikha S., Thiede C., Böhmer F.D. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood 2009, 113:3568-3576.
28. Schnittger S., Dicker F., Kern W., Wendland N., Sundermann J., Alpermann T., Haferlach C., Haferlach T. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011, 117:2348-2357.
29. Schwarz B.A., Sambandam A., Maillard I., Harman B.C., Love P.E., Bhandoola A. Selective thymus settling regulated by cytokine and chemokine receptors. J.Immunol. 2007, 178:2008-2017.
30. Sitnicka E., Bryder D., Theilgaard-Mönch K., Buza-Vidas N., Adolfsson J., Jacobsen S.E. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 2002, 17:463-472.
31. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
32. Steidl U., Rosenbauer F., Verhaak R.G., Gu X., Ebralidze A., Otu H.H., Klippel S., Steidl C., Bruns I., Costa D.B., et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat. Genet. 2006, 38:1269-1277.
33. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 2003, 3:650-665.